A large body of literature has demonstrated that aberrant epidermal growth factor receptor (EGFR) pathway activity is a backbone of NSCLC cancerogenesis, playing a considerable role in processes decreased in malignancies, such as cell proliferation, differentiation and migration (Bardelli et al., 2003; Sawyers, 2003; Ciardiello and Tortora, 2008). This evidence concerns the gene EGFR and non-small cell lung carcinoma.